Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18629790 | 0.84 | HSD17B10 (0.57) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL29563708 | 0.84 | HSD17B10 (0.57) | SMN1; SMN2RAB9ANPC1MAPK1MAPT | |
| SCHEMBL1849856 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL30008144 | 0.82 | RAB9A (1.00) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL30008478 | 0.82 | L3MBTL1 (0.91) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL3403751 | 0.81 | TSHR (0.68) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL24616562 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL1848388 | 0.79 | L3MBTL1 (0.72) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL24738246 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 | |
| SCHEMBL24738248 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | SMN1; SMN2 1852/4885RAB9A 2566/4885NPC1 292/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | SMN1; SMN2 1852/4885RAB9A 2566/4885NPC1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.